Business Lists and Databases Available for Marketing and Research - Direct Mailing Emailing Calling
NAICS Code 624190-49 - Heart Disease Information & Treatment
Marketing Level - NAICS 8-DigitBusiness Lists and Databases Available for Marketing and Research
Business List Pricing Tiers
Quantity of Records | Price Per Record | Estimated Total (Max in Tier) |
---|---|---|
0 - 1,000 | $0.25 | Up to $250 |
1,001 - 2,500 | $0.20 | Up to $500 |
2,501 - 10,000 | $0.15 | Up to $1,500 |
10,001 - 25,000 | $0.12 | Up to $3,000 |
25,001 - 50,000 | $0.09 | Up to $4,500 |
50,000+ | Contact Us for a Custom Quote |
What's Included in Every Standard Data Package
- Company Name
- Contact Name (where available)
- Job Title (where available)
- Full Business & Mailing Address
- Business Phone Number
- Industry Codes (Primary and Secondary SIC & NAICS Codes)
- Sales Volume
- Employee Count
- Website (where available)
- Years in Business
- Location Type (HQ, Branch, Subsidiary)
- Modeled Credit Rating
- Public / Private Status
- Latitude / Longitude
- ...and more (Inquire)
Boost Your Data with Verified Email Leads
Enhance your list or opt for a complete 100% verified email list – all for just $0.10 per email!
NAICS Code 624190-49 Description (8-Digit)
Parent Code - Official US Census
Tools
Tools commonly used in the Heart Disease Information & Treatment industry for day-to-day tasks and operations.
- Electrocardiogram (ECG)
- Echocardiogram
- Cardiac catheterization
- Angioplasty
- Stent placement
- Coronary artery bypass surgery
- Pacemaker
- Implantable cardioverter defibrillator (ICD)
- Blood pressure monitor
- Cholesterol-lowering medications
- Aspirin
- Beta blockers
- Calcium channel blockers
- ACE inhibitors
- Diuretics
- Nitroglycerin
- Statins
- Heart rate monitor
- Exercise equipment
Industry Examples of Heart Disease Information & Treatment
Common products and services typical of NAICS Code 624190-49, illustrating the main business activities and contributions to the market.
- Cardiac rehabilitation programs
- Heart disease support groups
- Heart disease education classes
- Heart disease clinics
- Cardiology practices
- Heart disease research organizations
- Heart disease treatment centers
- Heart disease prevention programs
- Heart disease screening services
- Heart disease diagnostic services
History
A concise historical narrative of NAICS Code 624190-49 covering global milestones and recent developments within the United States.
- The history of the "Heart Disease Information & Treatment" industry dates back to the early 20th century when the first heart surgeries were performed. In 1896, Ludwig Rehn performed the first successful heart surgery by removing a knife from a patient's heart. In 1951, the first successful open-heart surgery was performed by Dr. F. John Lewis. In the 1960s, the first pacemaker was implanted, and in the 1970s, the first coronary artery bypass surgery was performed. In the United States, the American Heart Association was founded in 1924 to promote heart health and research. In 1948, the Framingham Heart Study began, which was a long-term study that identified risk factors for heart disease. In the 1980s, the first statin drugs were introduced to lower cholesterol levels, and in the 1990s, the first stents were used to keep arteries open. Today, the industry continues to advance with new treatments and technologies. In recent history, the "Heart Disease Information & Treatment" industry in the United States has seen significant advancements. In 2013, the American College of Cardiology and the American Heart Association released new guidelines for the treatment of cholesterol, which emphasized the use of statins. In 2015, the FDA approved a new class of cholesterol-lowering drugs called PCSK9 inhibitors. In 2016, the first leadless pacemaker was approved for use in the United States. In 2017, the FDA approved a new heart failure drug called Entresto. In 2019, the FDA approved a new transcatheter aortic valve replacement (TAVR) device for patients with severe aortic stenosis. These advancements have improved the treatment and outcomes for patients with heart disease in the United States.